Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth

Clearmind Medicine has reflected on a transformative 2025, highlighting key clinical advancements, expanded global reach, and strengthened foundation for future growth. The company achieved significant milestones in its FDA-approved Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic MEAI-based oral compound for treating Alcohol Use Disorder. Clearmind advanced the trial, completed first-in-human dosing, reported positive top-line safety and tolerability results, and expanded its intellectual property portfolio and pipeline. Looking ahead to 2026, Clearmind remains focused on advancing its pipeline, generating additional clinical data, and exploring strategic opportunities to maximize shareholder value and patient impact.